Emerging drugs in chronic myelogenous leukaemia

Bibliography

• DE KLEIN A, VAN KESSEL AG, GROSVELD G et al.: A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature (1982) 300:765-767.
   PubMed Web of Science ®Google Scholar
• SHTIVELMAN E, LIFSHITZ B, GALE RP, CANAANI E: Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature (1985) 315:550-554.
   PubMed Web of Science ®Google Scholar
• KLOETZER W, KURZROCK R, SMITH L et al.: The human cellular abl gene product in the chronic myelogenous leukemia cell line K562 has an associated tyrosine protein kinase activity. Virology (1985) 140:230-238.
   PubMed Web of Science ®Google Scholar
• HEHLMANN R, HEIMPEL H, HASFORD J et al.: Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group. Blood (1993) 82:398-407.
   PubMed Web of Science ®Google Scholar
• GUILHOT F, ROY L, GUILHOT J, MILLOT F: Interferon therapy in chronic myelogenous leukemia. Hematol. Oncol. Clin. North Am. (2004) 18:585-603, viii.
   PubMed Web of Science ®Google Scholar
• NO AUTHORS LISTED: Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials: Chronic Myeloid Leukemia Trialists’ Collaborative Group. J. Natl. Cancer Inst. (1997) 89:1616-1620.
   PubMed Web of Science ®Google Scholar
• THOMAS ED, CLIFT RA, FEFER A et al.: Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann. Intern. Med. (1986) 104:155-163.
   PubMed Web of Science ®Google Scholar
• DRUKER BJ, TAMURA S, BUCHDUNGER E et al.: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of BCR–ABL positive cells. Nat. Med. (1996) 2:561-566.
   PubMed Web of Science ®Google Scholar
• DRUKER BJ, TALPAZ M, RESTA DJ et al.: Efficacy and safety of a specific inhibitor of the BCR–ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. (2001) 344:1031-1037.
   PubMed Web of Science ®Google Scholar
• KANTARJIAN H, SAWYERS C, HOCHHAUS A et al.: Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N. Engl. J. Med. (2002) 346:645-652.
   PubMed Web of Science ®Google Scholar
• TALPAZ M, SILVER RT, DRUKER BJ et al.: Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a Phase II study. Blood (2002) 99:1928-1937.
   PubMed Web of Science ®Google Scholar
• SAWYERS CL, HOCHHAUS A, FELDMAN E et al.: Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a Phase II study. Blood (2002) 99:3530-3539.
   PubMed Web of Science ®Google Scholar
• OTTMANN OG, DRUKER BJ, SAWYERS CL et al.: A Phase II study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood (2002) 100:1965-1971.
   PubMed Web of Science ®Google Scholar
• O’BRIEN S, GUILHOT F, LARSON RA et al.: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. (2003) 348:994-1004.
   PubMed Web of Science ®Google Scholar
• HASFORD J, PFIRRMANN M, HOCHHAUS A: How long will chronic myeloid leukemia patients treated with imatinib mesylate live? Leukemia (2005) 19:497-499.
   PubMed Web of Science ®Google Scholar
• DRUKER B: Long-term benefit of imatinib for patients newly diagnosed with chronic myeloid leukemia in chronic phase: the 5-year update from IRIS study. 2006 ASCO Annual meeting. Atlanta, GA, USA (2006).
   Google Scholar
• HOCHHAUS A, HUGHES T: Clinical resistance to imatinib: mechanisms and implications. Hematol. Oncol. Clin. North Am. (2004) 18:641-656, ix.
   PubMed Web of Science ®Google Scholar
• CORTES J: Overcoming drug resistance in chronic myeloid leukemia. Curr. Opin. Hematol. (2006) 13:79-86.
   PubMed Web of Science ®Google Scholar
• BHATIA R, HOLTZ M, NIU N et al.: Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood (2003) 101:4701-4707.
   PubMed Web of Science ®Google Scholar
• GRAHAM SM, JORGENSEN HG, ALLAN E et al.: Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI-571 in vitro. Blood (2002) 99:319-325.
   PubMed Web of Science ®Google Scholar
• HUGHES TP, KAEDA J, BRANFORD S et al.: Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N. Engl. J. Med. (2003) 349:1423-1432.
   PubMed Web of Science ®Google Scholar
• COWAN-JACOB SW, GUEZ V, FENDRICH G et al.: Imatinib (STI-571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment. Mini Rev. Med. Chem. (2004) 4:285-299.
   PubMed Web of Science ®Google Scholar
• TAUCHI T, OHYASHIKI K: Molecular mechanisms of resistance of leukemia to imatinib mesylate. Leuk. Res. (2004) 28(Suppl. 1):S39-S45.
   PubMed Web of Science ®Google Scholar
• VON BUBNOFF N, SCHNELLER F, PESCHEL C, DUYSTER J: BCR–ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI-571: a prospective study. Lancet (2002) 359:487-491.
   PubMed Web of Science ®Google Scholar
• TANIS KQ, VEACH D, DUEWEL HS, BORNMANN WG, KOLESKE AJ: Two distinct phosphorylation pathways have additive effects on Abl family kinase activation. Mol. Cell. Biol. (2003) 23:3884-3896.
   PubMed Web of Science ®Google Scholar
• GORRE ME, MOHAMMED M, ELLWOOD K et al.: Clinical resistance to STI-571 cancer therapy caused by BCR–ABL gene mutation or amplification. Science (2001) 293:876-880.
   PubMed Web of Science ®Google Scholar
• HOCHHAUS A, KREIL S, CORBIN AS et al.: Molecular and chromosomal mechanisms of resistance to imatinib (STI-571) therapy. Leukemia (2002) 16:2190-2196.
   PubMed Web of Science ®Google Scholar
• SHAH NP, NICOLL JM, NAGAR B et al.: Multiple BCR–ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI-571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell (2002) 2:117-125.
   PubMed Web of Science ®Google Scholar
• BRANFORD S, RUDZKI Z, WALSH S et al.: High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI-571) resistance. Blood (2002) 99:3472-3475.
   PubMed Web of Science ®Google Scholar
• BRANFORD S, HUGHES T: Detection of BCR–ABL mutations and resistance to imatinib mesylate. Methods Mol. Med. (2006) 125:93-106.
   PubMedGoogle Scholar
• BRANFORD S, RUDZKI Z, WALSH S et al.: Detection of BCR–ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood (2003) 102:276-283.
   PubMed Web of Science ®Google Scholar
• HOCHHAUS A, LA ROSEE P: Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia (2004) 18:1321-1331.
   PubMed Web of Science ®Google Scholar
• FERRAO PT, FROST MJ, SIAH SP, ASHMAN LK: Overexpression of P-glycoprotein in K562 cells does not confer resistance to the growth inhibitory effects of imatinib (STI-571) in vitro. Blood (2003) 102:4499-4503.
   PubMed Web of Science ®Google Scholar
• GAMBACORTI-PASSERINI C, BARNI R, LE COUTRE P et al.: Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR–ABL(+) leukemic cells to the abl inhibitor STI-571. J. Natl. Cancer Inst. (2000) 92:1641-1650.
   PubMed Web of Science ®Google Scholar
• HUGHES T, DEININGER M, HOCHHAUS A et al.: Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR–ABL transcripts and kinase domain mutations and for expressing results. Blood (2006) 108:28-37.
   PubMed Web of Science ®Google Scholar
• MERX K, MULLER MC, KREIL S et al.: Early reduction of BCR–ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha. Leukemia (2002) 16:1579-1583.
   PubMed Web of Science ®Google Scholar
• MULLER MC, GATTERMANN N, LAHAYE T et al.: Dynamics of BCR–ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C. Leukemia (2003) 17:2392-2400.
   PubMed Web of Science ®Google Scholar
• WANG L, PEARSON K, FERGUSON JE, CLARK RE: The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia. Br. J. Haematol. (2003) 120:990-999.
   PubMed Web of Science ®Google Scholar
• ELRICK LJ, JORGENSEN HG, MOUNTFORD JC, HOLYOAKE TL: Punish the parent not the progeny. Blood (2005) 105:1862-1866.
   PubMed Web of Science ®Google Scholar
• DEININGER MW, HOLYOAKE TL: Can we afford to let sleeping dogs lie? Blood (2005) 105:1840-1841.
   PubMed Web of Science ®Google Scholar
• CORTES J, O’BRIEN S, KANTARJIAN H: Discontinuation of imatinib therapy after achieving a molecular response. Blood (2004) 104:2204-2205.
   PubMed Web of Science ®Google Scholar
• WEISBERG E, MANLEY PW, BREITENSTEIN W et al.: Characterization of AMN-107, a selective inhibitor of native and mutant Bcr–Abl. Cancer Cell (2005) 7:129-141.
   PubMed Web of Science ®Google Scholar
• LA ROSEE P, CORBIN AS, STOFFREGEN EP, DEININGER MW, DRUKER BJ: Activity of the Bcr–Abl kinase inhibitor PD-180970 against clinically relevant Bcr–Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI-571). Cancer Res. (2002) 62:7149-7153.
   PubMed Web of Science ®Google Scholar
• SHAH NP, TRAN C, LEE FY, CHEN P, NORRIS D, SAWYERS CL: Overriding imatinib resistance with a novel ABL kinase inhibitor. Science (2004) 305:399-401.
   PubMed Web of Science ®Google Scholar
• TOKARSKI JS, NEWITT JA, CHANG CY et al.: The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res. (2006) 66:5790-5797.
   PubMed Web of Science ®Google Scholar
• KANTARJIAN H, GILES F, WUNDERLE L et al.: Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N. Engl. J. Med. (2006) 354:2542-2551.
   PubMed Web of Science ®Google Scholar
• TALPAZ M, SHAH NP, KANTARJIAN H et al.: Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N. Engl. J. Med. (2006) 354:2531-2541.
   PubMed Web of Science ®Google Scholar
• BRUNNER TB, HAHN SM, GUPTA AK, MUSHEL RJ, MCKENNA WG, BERNHARD EJ: Farnesyltransferase inhibitors: an overview of the results of preclinical and clinical investigations. Cancer Res. (2003) 63:5656-5668.
   PubMed Web of Science ®Google Scholar
• PETERS DG, HOOVER RR, GERLACH MJ et al.: Activity of the farnesyl protein transferase inhibitor SCH-66336 against BCR/ABL-induced murine leukaemia and primary cells from patients with chronic myeloid leukaemia. Blood (2001) 97:1402-1412.
   Google Scholar
• NAKAJIMA A, TAUCHI T, SUMI M et al.: Efficacy of SCH-663366, farnesyl transferase inhibitor, in conjunction with imatinib agaist BCR–ABL positive cells. Mol. Cancer Ther. (2003) 2:219-224.
   PubMed Web of Science ®Google Scholar
• BOCCHIA M, WENTWORTH PA, SOUTHWOOD S et al.: Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules. Blood (1995) 85:2680-2684.
   PubMed Web of Science ®Google Scholar
• BOSCH GJ, JOOSTEN AM, KESSLER JH, MELIEF CJ, LEEKSMA OC: Recognition of BCR–ABL positive leukemic blasts by human CD4+ T cells elicited by primary in vitro immunization with a BCR–ABL breakpoint peptide. Blood (1996) 88:3522-3527.
   PubMed Web of Science ®Google Scholar
• BOCCHIA M, KORONTSVIT T, XU Q et al.: Specific human cellular immunity to BCR–ABL oncogene-derived peptides. Blood (1996) 87:3587-3592.
   PubMed Web of Science ®Google Scholar
• CLARK RE, DODI IA, HILL SC et al.: Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR–ABL b3a2 fusion protein. Blood (2001) 98:2887-2893.
   PubMed Web of Science ®Google Scholar
• YASUKAWA M, OHMINAMI H, KOJIMA K et al.: HLA class II-restricted antigen presentation of endogenous bcr–abl fusion protein by chronic myelogenous leukemia-derived dendritic cells to CD4(+) T lymphocytes. Blood (2001) 98:1498-1505.
   PubMed Web of Science ®Google Scholar
• BOCCHIA M, GENTILI S, ABRUZZESE E et al.: Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet (2005) 365:657-662.
   PubMed Web of Science ®Google Scholar
• MOLLDREM JJ, LEE PP, WANG C et al.: Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat. Med. (2000) 6:1018-1023.
   PubMed Web of Science ®Google Scholar
• MENSSEN HD, RENKL HJ, RODECK U et al.: Presence of Wilms’ tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias. Leukemia (1995) 9:1060-1067.
   PubMed Web of Science ®Google Scholar
• BELLANTUONO I, GAO L, PARRY S et al.: Two distinct HLA-A0201-presented epitopes of the Wilms tumor antigen 1 can function as targets for leukemia-reactive CTL. Blood (2002) 100:3835-3837.
   PubMed Web of Science ®Google Scholar
• HOOS A, LEVEY DL: Vaccination with heat shock protein-peptide complexes: from basic science to clinical applications. Expert Rev. Vaccines (2003) 2:369-379.
   PubMedGoogle Scholar
• LI Z, QIAO Y, LIU B et al.: Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein and chronic myelogenous leukemia. Clin. Cancer Res. (2005) 11:4460-4468.
   PubMed Web of Science ®Google Scholar
• BANCHEREAU J, STEINMAN RM: Dendritic cells and the control of immunity. Nature (1998) 392:245-252.
   PubMed Web of Science ®Google Scholar
• WESTERMANN J, KOPP J, VAN LESSEN A et al.: Dendritic cells vaccination in BCR/ABL-positive chronic myeloid leukemia. Final results of a Phase I/II study. Blood (2004) 104:2943a.
   PubMed Web of Science ®Google Scholar
• VERSTOVSEK S, GILES FJ, QUINTAS-CARDAMA A et al.: Activity of AMN-107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cells. Leuk. Res. (2006) (In press).
   Google Scholar
• STOVER EH, CHEN J, LEE BH et al.: The small molecule tyrosine kinase inhibitor AMN-107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo. Blood (2005) 106:3206-3213.
   PubMed Web of Science ®Google Scholar
• GLEIXNER KV, MAYERHOFER M, AICHBERGER KJ et al.: PKC-412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN-107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. Blood (2006) 107:752-759.
   PubMed Web of Science ®Google Scholar
• PRENEN H, GUETENS G, DE BOECK G et al.: Cellular uptake of the tyrosine kinase inhibitors imatinib and AMN-107 in gastrointestinal stromal tumor cell lines. Pharmacology (2006) 77:11-16.
   PubMed Web of Science ®Google Scholar
• NAGAR B, BORNMANN WG, PELLICENA P et al.: Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD-173955 and imatinib (STI-571). Cancer Res. (2002) 62:4236-4243.
   PubMed Web of Science ®Google Scholar
• WEISBERG E, MANLEY P, MESTAN J, COWAN-JACOB S, RAY A, GRIFFIN JD: AMN-107 (nilotinib): a novel and selective inhibitor of BCR–ABL. Br. J. Cancer (2006) 94:1765-1769.
   PubMed Web of Science ®Google Scholar
• VON BUBNOFF N, MANLEY PW, MESTAN J, SANGER J, PESCHEL C, DUYSTER J: BcrR–Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN-107). Blood (2006) 108(4):1328-1333.
   PubMed Web of Science ®Google Scholar
• SATTLER M, MOHI MG, PRIDE YB et al.: Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell (2002) 1:479-492.
   PubMed Web of Science ®Google Scholar
• LE COUTRE P, GATTERMANN N, O’BRIEN S et al.: A Phase II study of nilotinib (AMN-107), a novel inhibitor of bcr–abl, administered to imatinib resitant and intolerant patients with chronic myelogenous leukemia in chronic phase (CP). Haematologica (2006) 91:377.
   PubMed Web of Science ®Google Scholar
• LOMBARDO LJ, LEE FY, CHEN P et al.: Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J. Med. Chem. (2004) 47:6658-6661.
   PubMed Web of Science ®Google Scholar
• FROST MJ, FERRAO PT, HUGHES TP, ASHMAN LK: Juxtamembrane mutant V560GKit is more sensitive to imatinib (STI-571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant. Mol. Cancer Ther. (2002) 1:1115-1124.
   PubMed Web of Science ®Google Scholar
• SAWYERS CL, SHAH NP, KANTARJIAN HM et al.: Hematologic and cytogenetic responses in imatinib-resistant chronic phase chronic myeloid leukemia patients treated with the dual SRC/ABL kinase inhibitor BMS-354825: results from a Phase I dose escalation study. Blood (2004) 104:10a.
   Google Scholar
• SCHITTENHELM M, SHIRAGA S, LEE FY, HEINRICH MC: BMS-354825 potently inhibits the kinase activity of KIT activation loop mutations associated with systemic mastocytosis and induces apoptosis of mastocytosis cell lines. Blood (2004) 104:666a.
   Google Scholar
• GUILHOT F: Imatinib-resistant CML: results of current clinical trials. In: 11th congress of the European Hematology Association. Novel strategies in the mangement of imatinib-resistant chronic myeloid leukemia (Satellite symposium). Europe ON (Ed.), Bristol-Myers Squibb Oncology, Amsterdam, The Netherlands (2006):52-61.
   Google Scholar
• HOCHHAUS A, KANTARJIAN H, SHAH NP et al.: A Phase II study of dasatinib in patients with chronic phase chronic myeloid leukemia who are resistant or intolerant to imatinib: results of the CA-180013 START-C study. Haematologica (2006) 91:170.
   Google Scholar
• KARP JE, LANCET JE, KAUFMANN SH et al.: Clinical and biologic activity of the farnesyl transferase inhibitor R-115777 in adults with refractoty and relapsed acute leukemias: a Phase I clinical–laboratory correlative trial. Blood (2001) 97:3361-3369.
   PubMed Web of Science ®Google Scholar
• BORTHAKUR G, KANTARJIAN H, DALEY GQ et al.: Pilot study of lonafarnib (SCH-66336, Sarasar) a farnesyl transferase inhibitor, in patients with chronic myeloid leukaemia in chronic or accelerated phase resistant or refractory to imatinib. Cancer (2006) 106:346-352.
   PubMed Web of Science ®Google Scholar
• CORTES J, GARCIA-MANERO G, O’BRIEN S et al.: A Phase I study of tipifarnib in combination with imatinib mesylate (IM) for patients with chronic myeloid leukaemia in chronic phase who had failed IM therapy. Blood (2004) 104:289a.
   Web of Science ®Google Scholar
• GOTLIB J, MAURO MJ, O’DWYER M et al.: Tipifarnib (Zarnestra) and imatinib (Gleevec) combination therapy in patients with advanced chronic myelogenous leukaemia (CML): prelimnary results of a Phase I study. Blood (2003) 102:909a.
   Google Scholar
• CORTES J, O’BRIEN S, VERSTOVSEK S et al.: Phase I study of lonafarnib (SCH-66336) in combination with IM for patients with chronic myeloid leukaemia (CML) after failure to imatinib. Blood (2004) 104:288.
   Web of Science ®Google Scholar
• COPLAND M, HAMILTON A, ELRICK LJ et al.: Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood (2006) 107:4532-4539.
   PubMed Web of Science ®Google Scholar
• MANNERING SI, MCKENZIE JL, FEARNLEY DB, HART DN: HLA-DR1-restricted BCR–ABL (b3a2)-specific CD4+ T lymphocytes respond to dendritic cells pulsed with b3a2 peptide and antigen-presenting cells exposed to b3a2 containing cell lysates. Blood (1997) 90:290-297.
   PubMed Web of Science ®Google Scholar
• CATHCART K, PINILLA-IBARZ J, KORONTSVIT T et al.: A multivalent BCR–ABL fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood (2004) 103:1037-1042.
   PubMed Web of Science ®Google Scholar
• PINILLA-IBARZ J, CATHCART K, KORONTSVIT T et al.: Vaccination of patients with chronic myelogenous leukemia with bcr–abl oncogene breakpoint fusion peptides generates specific immune responses. Blood (2000) 95:1781-1787.
   PubMed Web of Science ®Google Scholar
• TEN BOSCH GJ, KESSLER JH, JOOSTEN AM et al.: A BCR–ABL oncoprotein p210b2a2 fusion region sequence is recognized by HLA-DR2a restricted cytotoxic T lymphocytes and presented by HLA-DR matched cells transfected with an Ii(b2a2) construct. Blood (1999) 94:1038-1045.
   PubMed Web of Science ®Google Scholar
• BACCARANI M, SAGLIO G, GOLDMAN J et al.: Evolving concepts in the management of chronic myeloid leukemia. Recommendations from an expert panel on behalf of the European Leukemianet. Blood (2006) 108(6):1809-1820.
   PubMed Web of Science ®Google Scholar
• GUMIREDDY K, BAKER SJ, COSENZA SC et al.: A non-ATP-competitive inhibitor of BCR–ABL overrides imatinib resistance. Proc. Natl. Acad. Sci. USA (2005) 102:1992-1997.
   PubMed Web of Science ®Google Scholar
• YOUNG MA, SHAH NP, CHAO LH et al.: Structure of the kinase domain of an imatinib-resistant abl mutant in complex with the aurora kinase inhibitor VX-680. Cancer Res. (2006) 66:1007-1014.
   PubMed Web of Science ®Google Scholar
• DRUKER BJ, SAWYERS CL, KANTARJIAN H et al.: Activity of a specific inhibitor of the BCR–ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. (2001) 344:1038-1042.
   PubMed Web of Science ®Google Scholar